Novavax, Inc.
NVAXNASDAQHealthcare● Active
$8.76
$-0.73(-7.65%)
Market Cap$1.4B
P/E Ratio—
52W High$11.97
52W Low$6.13
Novavax, Inc. (NVAX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NVAX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.12B | $0.68B | $0.56B | $1.60B | $0.20B |
| Cost of Revenue | $0.07B | $0.20B | $0.34B | $0.90B | $0.00B |
| Gross Profit | $1.05B | $0.48B | $0.21B | $0.70B | $0.20B |
| Gross Margin %(computed) | 93.67% | 70.28% | 38.21% | 43.55% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.34B | $0.39B | $0.74B | $1.24B | $2.53B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.49B | $0.30B |
| Total Operating Expenses | $0.49B | $0.73B | $0.78B | $1.34B | $1.88B |
| Operating Income | $0.56B | ($0.25B) | ($0.57B) | ($0.64B) | ($1.69B) |
| Operating Margin %(computed) | 50.14% | -36.49% | -101.82% | -40.32% | -853.61% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.02B | $0.02B | $0.01B | $0.02B | $0.02B |
| Income Before Tax | $0.44B | ($0.18B) | ($0.54B) | ($0.65B) | ($1.71B) |
| Income Tax Expense | $0.00B | $0.01B | $0.00B | $0.00B | $0.03B |
| Net Income | $0.44B | ($0.19B) | ($0.55B) | ($0.66B) | ($1.74B) |
| Net Margin %(computed) | 39.19% | -27.49% | -97.97% | -41.15% | -882.55% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.72 | $-1.23 | $-5.41 | $-8.42 | $-23.44 |
| Wtd Avg Shares | 0.16B | 0.15B | 0.10B | 0.08B | 0.07B |
| EBITDA | $0.49B | ($0.11B) | ($0.49B) | ($0.60B) | ($1.68B) |
| EBITDA Margin %(computed) | 43.82% | -15.84% | -87.60% | -37.82% | -850.66% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Novavax, Inc. data
About Novavax, Inc. (NVAX) Income Statement
Novavax, Inc. (NVAX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NVAX reported revenue of $1.12B, gross profit of $1.05B (gross margin 93.67%), and net income of $0.44B — a net profit margin of 39.19%.
Frequently asked questions
NVAX · 4 questionsNovavax, Inc. (NVAX) reported revenue of $1.12B for 2025, up 64.7% year-over-year.
NVAX revenueNVAX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08